Health TrialsbyHealthPanel

Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients

ConditionsGlioblastomaSquamous Cell CarcinomaHodgkin LymphomaNon-hodgkin LymphomaBreast CancerProstate CancerGastric CancerOvarian CancerAcute LeukemiaPancreatic CancerSpindle Cell SarcomaCancerTumor, SolidTumor, BrainEsophageal AndeocarcinomaMixed Phenotype AMLDesmoplastic Round Cell Sarcoma
Trial statusAvailable
Trial phaseNot listed
Trial typeExpanded Access
Biological sexAll
AgeNot listed
SponsorAVM Biotechnology Inc

About this trial

AVM Biotechnology, Inc., provides immunomodulatory AVM0703 to solid tumor and blood cancer patients upon request by a US licensed MD or DO. As of July 2024, 37 patients have been treated through this FDA-EAP including patients diagnosed with relapsed or recurring glioblastoma, inoperable/chemotherapy ineligible CNS Squamous Cell Carcinoma, metastatic Breast Cancer, ovarian cancer, gastric cancer, Hodgkin's Lymphoma, Mixed Phenotype Acute Myelogenous Leukemia, colon cancer, B-ALL, Malignant Myxoid Spindle Cell Neoplasm, non-small cell lung cancer, DLBCL with CNS involvement, metastatic prostate cancer, Anaplastic T-cell Non-Hodgkin's Lymphoma and metastatic pancreatic cancer. Drug-related side-effects are predominantly grade 1 and include itching during the infusion and about 1 week of low grade insomnia.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

None

Trial design

Treatments tested in this trial

  • AVM0703

    Drug

    small molecule immunomodulatory drug

  • Hydrocortisone

    Drug

    physiologic circadian glucocorticoid

  • Proton pump inhibitor

    Drug

Treatment groups

No treatment groups listed

Trial outcomes

This trial has no outcomes listed.

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

AVM Biotechnology Inc

Lead sponsor

Source ClinicalTrials.gov
Apply now